A Study to Find a Suitable Dose of ASP2802 in People With CD20-positive B-cell Lymphomas
Clinical trial NCT06248086 · TERMINATED
Trial details
- NCT number
- NCT06248086
- Sponsor
- Astellas Pharma Global Development, Inc.
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2024-09-06
- Primary completion
- 2024-12-01
- Enrollment
- 1
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.